1999•Bone Marrow TransplantationRequires access

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease

DE Reece, TJ Nevill, Antoine Sayegh, JJ Spinelli, DA Brockington, MJ Barnett, H-G Klingemann, JM Connors, S.H. Nantel, JD Shepherd, HJ Sutherland, NJS Voss, RN Fairey, SE O’Reilly, GL Phillips

Open publisher page 33 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 33 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Carmustine, Etoposide, Medicine, Cyclophosphamide, Cisplatin, Regimen, Toxicity, Transplantation

Back to paper search Browse research topics Original source

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease — Research Paper | ScholarLens